{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05664789",
            "orgStudyIdInfo": {
                "id": "IRB-63262"
            },
            "secondaryIdInfos": [
                {
                    "id": "4R00HD101702-03",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/4R00HD101702-03"
                }
            ],
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial",
            "officialTitle": "Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: A Randomized, Controlled Trial",
            "therapeuticArea": [
                "Other"
            ],
            "study": "targeting-the-neurobiology-of-rrb-in-autism-using-n-acetylcysteine-trial"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-04-26",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-01-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-01-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-12-07",
            "studyFirstSubmitQcDate": "2022-12-15",
            "studyFirstPostDateStruct": {
                "date": "2022-12-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "John Patrick Hegarty",
                "investigatorTitle": "Clinical Assistant Professor",
                "investigatorAffiliation": "Stanford University"
            },
            "leadSponsor": {
                "name": "Stanford University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder. This is a 12-week double-blind, randomized, placebo-controlled trial of NAC."
        },
        "conditionsModule": {
            "conditions": [
                "Autism Spectrum Disorder"
            ],
            "keywords": [
                "Magnetic resonance imaging",
                "N-acetyl cysteine",
                "Restricted and repetitive behaviors",
                "Electroencephalography"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2",
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Double-blind, randomized, placebo-controlled trial 2 arms, N-acetylcysteine and placebo",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "maskingDescription": "The placebo compound will match the active N-acetylcysteine in appearance, odor, taste, and packaging.",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 48,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "N-acetylcysteine",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "12 week administration of active study compound",
                    "interventionNames": [
                        "Drug: N acetyl cysteine"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "12 week administration of matched placebo",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "N acetyl cysteine",
                    "description": "N-acetylcysteine (NAC) is an over-the-counter dietary supplement that is relatively well tolerated and exhibits minimal side effects, even at high dosages. N",
                    "armGroupLabels": [
                        "N-acetylcysteine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "matched placebo",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in Children's Yale Brown-Obsessive Compulsive Scale for Autism Spectrum Disorder (CYBOCS-ASD) at 12 weeks",
                    "description": "Severity of restricted and repetitive behaviors, higher scores indicate more severe behaviors",
                    "timeFrame": "Screening and week 12"
                },
                {
                    "measure": "Change in Glutamatergic neurometabolites at 12 weeks",
                    "description": "Glu and Glx measured by magnetic resonance imaging",
                    "timeFrame": "Baseline and week 12"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in Restricted and Repetitive Behavior Scale Revised (RBS-R) at 12 weeks",
                    "description": "Severity of restricted and repetitive behaviors, higher scores indicate more severe behaviors",
                    "timeFrame": "Baseline and week 12"
                },
                {
                    "measure": "Change in Gamma band activity at 12 weeks",
                    "description": "Electrical activity between 30-48 Hz measured by electroencephalography",
                    "timeFrame": "Baseline and week 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* children between 3 years and 12 years 11 months\n* diagnosis of autism spectrum disorder confirmed with the Autism Diagnostic Interview- Revised and the Autism Diagnostic Observation Schedule-2, Brief Observation of Symptoms of Autism, or Childhood Autism Rating Scale\n* at least moderate severity of restricted and repetitive behaviors defined by a Children's Yale-Brown Obsessive Compulsive Scale for Autism Spectrum Disorder score \u2265 11\n* physical development indicative of prepubescence as defined by criteria for Tanner Stage 1\n* if home address is within 300 miles of the primary study site, participants must pass MR safety screening (e.g., no metal in the body) and attempt baseline neuroimaging (MRI or EEG), otherwise baseline neuroimaging is not required for participation\n* have stable medication regimens (\u2265 30 days) and psychosocial treatments (\u2265 60 days) prior to randomization with no anticipated changes during the trial\n\nExclusion Criteria:\n\n* presence of known genetic abnormalities associated with ASD (e.g. Fragile X)\n* current or life-time diagnosis of severe psychiatric disorder (e.g., schizophrenia)\n* presence of significant medical problems\n* the inability of at least one caregiver to speak and read English to a sufficient level\n* participants taking glutathione agents/prodrugs\n* history of any adverse effects to glutathione agents/prodrugs\n* the inability to drink a sample study compound dissolved in liquid",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "3 Years",
            "maximumAge": "12 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Brianna Alconcher",
                    "role": "CONTACT",
                    "phone": "(650)723-7845",
                    "email": "autismresearch@stanford.edu"
                },
                {
                    "name": "John Hegarty, PhD",
                    "role": "CONTACT",
                    "phone": "(650)723-7845",
                    "email": "autismresearch@stanford.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "John Hegarty, PhD",
                    "affiliation": "Stanford University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Department of Psychiatry and Behavioral Sciences",
                    "status": "RECRUITING",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94304",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Brianna Alconcher",
                            "role": "CONTACT",
                            "phone": "650-723-7845",
                            "email": "autismresearch@stanford.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "De-Identified data will be shared with the National Database for Autism Research (NDAR)",
            "timeFrame": "The data will be shared on January 15th and July 15th each year",
            "accessCriteria": "Researchers with access to the National Database for Autism Research (NDAR) will be able to obtain the submitted data",
            "url": "http://nda.nih.gov"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001321",
                    "term": "Autistic Disorder"
                },
                {
                    "id": "D000067877",
                    "term": "Autism Spectrum Disorder"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002659",
                    "term": "Child Development Disorders, Pervasive"
                },
                {
                    "id": "D000065886",
                    "term": "Neurodevelopmental Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4623",
                    "name": "Autistic Disorder",
                    "asFound": "Autism",
                    "relevance": "HIGH"
                },
                {
                    "id": "M206",
                    "name": "Autism Spectrum Disorder",
                    "asFound": "Autism Spectrum Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5903",
                    "name": "Child Development Disorders, Pervasive",
                    "relevance": "LOW"
                },
                {
                    "id": "M5902",
                    "name": "Developmental Disabilities",
                    "relevance": "LOW"
                },
                {
                    "id": "M30644",
                    "name": "Neurodevelopmental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000111",
                    "term": "Acetylcysteine"
                },
                {
                    "id": "C000030905",
                    "term": "N-monoacetylcystine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000005100",
                    "term": "Expectorants"
                },
                {
                    "id": "D000019141",
                    "term": "Respiratory System Agents"
                },
                {
                    "id": "D000016166",
                    "term": "Free Radical Scavengers"
                },
                {
                    "id": "D000000975",
                    "term": "Antioxidants"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000020011",
                    "term": "Protective Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000931",
                    "term": "Antidotes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3475",
                    "name": "Acetylcysteine",
                    "asFound": "Biochemical",
                    "relevance": "HIGH"
                },
                {
                    "id": "M244107",
                    "name": "N-monoacetylcystine",
                    "asFound": "ACE",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M8243",
                    "name": "Expectorants",
                    "relevance": "LOW"
                },
                {
                    "id": "M21137",
                    "name": "Respiratory System Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4292",
                    "name": "Antioxidants",
                    "relevance": "LOW"
                },
                {
                    "id": "M21869",
                    "name": "Protective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4250",
                    "name": "Antidotes",
                    "relevance": "LOW"
                },
                {
                    "id": "T4",
                    "name": "Cysteine",
                    "asFound": "Estrogen",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "Resp",
                    "name": "Respiratory System Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}